Penn Capital Management Company LLC Takes Position in Nurix Therapeutics, Inc. $NRIX

Penn Capital Management Company LLC acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 32,983 shares of the company’s stock, valued at approximately $800,000.

Other institutional investors have also recently modified their holdings of the company. Larson Financial Group LLC lifted its position in shares of Nurix Therapeutics by 339.0% in the fourth quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after acquiring an additional 1,190 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Nurix Therapeutics by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 68,019 shares of the company’s stock valued at $1,290,000 after acquiring an additional 1,476 shares during the last quarter. Intesa Sanpaolo Wealth Management acquired a new stake in shares of Nurix Therapeutics during the fourth quarter valued at $31,000. Royal Bank of Canada increased its position in Nurix Therapeutics by 17.6% during the 4th quarter. Royal Bank of Canada now owns 10,842 shares of the company’s stock worth $206,000 after purchasing an additional 1,623 shares in the last quarter. Finally, Arizona State Retirement System increased its position in Nurix Therapeutics by 8.2% during the 4th quarter. Arizona State Retirement System now owns 21,990 shares of the company’s stock worth $417,000 after purchasing an additional 1,674 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Friday, July 17th. UBS Group lifted their price target on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Needham & Company LLC reissued a “buy” rating and issued a $34.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, August 4th. Stifel Nicolaus boosted their price objective on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Finally, Jefferies Financial Group upped their price objective on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, June 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $34.21.

Nurix Therapeutics Trading Down 2.5%

Nurix Therapeutics stock opened at $26.21 on Friday. The firm has a market capitalization of $2.72 billion, a P/E ratio of -7.60 and a beta of 1.79. The stock has a fifty day moving average price of $24.37 and a 200 day moving average price of $18.99. Nurix Therapeutics, Inc. has a 52 week low of $8.19 and a 52 week high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The business had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $15.29 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. As a group, equities analysts predict that Nurix Therapeutics, Inc. will post -2.73 EPS for the current year.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 4,761 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the transaction, the chief financial officer directly owned 40,166 shares of the company’s stock, valued at $978,443.76. This trade represents a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 5,394 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.00, for a total value of $107,880.00. Following the transaction, the insider owned 115,005 shares in the company, valued at approximately $2,300,100. This represents a 4.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,314 shares of company stock worth $589,361 over the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.